Free Trial
NASDAQ:IMMX

Immix Biopharma Q3 2023 Earnings Report

Immix Biopharma logo
$2.21 +0.26 (+13.33%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immix Biopharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.23
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Immix Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immix Biopharma Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Sunday, November 12, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Immix Biopharma's Q1 2025 earnings is scheduled for Monday, August 11, 2025

Earnings Documents

Immix Biopharma Earnings Headlines

Immix Biopharma Inc.
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Immix Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

View Immix Biopharma Profile

More Earnings Resources from MarketBeat